Propel Bio Management, LLC
- SEC CIK
- 0001969764
- Latest filing
- Aug 13, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 15, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 18
- −3 vs. Q4 2024
- Portfolio value
- $86.1M
- −$14.6M (−14.5%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PAGPPlains GP Holdings LP | LTD PARTNR INT A | 1,272,360 | $27.2M | 31.6% | 00.0% | Unchanged | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 30,032 | $9.95M | 11.6% | −13,000−30.2% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 228,884 | $9.27M | 10.8% | −114,845−33.4% | Reduced | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 1,134,927 | $7.12M | 8.3% | +145,000+14.6% | Added | History |
| ACHVAchieve Life Sciences, Inc. | COM | 2,453,092 | $6.55M | 7.6% | 00.0% | Unchanged | History |
| APLTApplied Therapeutics, Inc. | COM | 11,285,420 | $5.52M | 6.4% | +1,670,000+17.4% | Added | History |
| Avidity Biosciences, Inc.05370A108 | COM | 178,500 | $5.27M | 6.1% | 00.0% | Unchanged | – |
| ABEOAbeona Therapeutics Inc. | COM NEW | 624,022 | $2.97M | 3.5% | 00.0% | Unchanged | History |
| TCRXTScan Therapeutics, Inc. | COM | 2,087,139 | $2.88M | 3.3% | 00.0% | Unchanged | History |
| DCTHDelcath Systems, Inc. | COM NEW | 177,600 | $2.26M | 2.6% | +160,600+944.7% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 183,259 | $2.25M | 2.6% | 00.0% | Unchanged | History |
| ZVRAZevra Therapeutics, Inc. | COM NEW | 179,874 | $1.35M | 1.6% | 00.0% | Unchanged | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 1,451,557 | $1.16M | 1.3% | +1,451,557 | New | History |
| Maat Pharma SacaF5888J116 | COMM | 166,423 | $1.04M | 1.2% | +163,272+5,181.6% | Added | – |
| CMPXCompass Therapeutics, Inc. | COM | 228,317 | $433.8K | 0.5% | +228,317 | New | History |
| LONALeonaBio, Inc. | COM | 1,492,792 | $425.3K | 0.5% | 00.0% | Unchanged | History |
| EIGREiger BioPharmaceuticals, Inc. | COM NEW | 146,381 | $423.0K | 0.5% | 00.0% | Unchanged | History |
| Contra Chinook Therapeu169CVR016 | COM | 79,357 | $38.5K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q4 2024 (5)
Positions held at the end of Q4 2024 that are gone from this filing.
| Security | Class | Shares in Q4 2024 | Value in Q4 2024 | % of portfolio in Q4 2024 | History |
|---|---|---|---|---|---|
| ARDXArdelyx, Inc. | COM | 950,947 | $4.82M | 4.8% | History |
| KYMRKymera Therapeutics, Inc. | COM | 56,359 | $2.27M | 2.3% | History |
| KURAKura Oncology, Inc. | COM | 130,000 | $1.13M | 1.1% | History |
| JSPRJasper Therapeutics, Inc. | COM NEW | 20,000 | $427.6K | 0.4% | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 25,209 | $95.3K | 0.1% | History |